Back to results
US 12,005,064 B2Granted
Pharmaceutical composition comprising non-ionic surfactants
AssigneesHoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
InventorsSusanne Meier, Carsten Bruesewitz
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising poorly soluble compounds such as BSC class II or IV kinase inhibitors, a process for the preparation thereof and its use in the treatment of diseases, in particular cancer, further particularly in non-small lung cancer.
Claims41
A pharmaceutical composition comprising:
- a) 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-l -yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride,
- b) a non-ionic surfactant A that is a solid at room temperature that is vitamin E polyethylene glycol succinate, and
- c) a non-ionic surfactant B that is liquid at room temperature that is polysorbate 80, wherein the HLB of surfactants A and B are independently equal or greater than 8 and wherein 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-l -yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride is dispersed in the matrix formed by surfactants A and B.
A pharmaceutical composition comprising:
- a) 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-l -yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride,
- b) a non-ionic surfactant A that is a solid at room temperature that is vitamin E polyethylene glycol succinate, and
- c) a non-ionic surfactant B that is liquid at room temperature that is polysorbate 80,
- wherein the HLB of surfactants A and B are independently equal or greater than 8,
- wherein 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-l -yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride is dispersed in the matrix formed by surfactants A and B, and
- wherein the pharmaceutical composition is obtainable by:
- a) melting surfactant A,
- b) mixing melted surfactant A and liquid surfactant B, and
- c) suspending 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-l-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride in the obtained mixture.
6 more elements
A pharmaceutical composition comprising:
- a) 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-1 1-oxo-6, 1 1-dihydro-5H-benzo[b]carbaxole-3-carbonitrile hydrochloride,
- b) a non-ionic surfactant A that is a solid at room temperature that is lauroyl polyoxylglyceride, and
- c) a non-ionic surfactant B that is liquid at room temperature that is polysorbate 80,
- wherein the HLB of surfactants A and B are independently equal or greater than 8 and
- wherein 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-1 1-oxo-6, 1 1-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride is dispersed in the matrix formed by surfactants A and B.
2 more elements
A pharmaceutical composition comprising:
- a) 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-1 1-oxo-6, 1 1-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride,
- b) a non-ionic surfactant A that is a solid at room temperature that is lauroyl polyoxylglyceride, and
- c) a non-ionic surfactant B that is liquid at room temperature that is polysorbate 80,
- wherein the HLB of surfactants A and B are independently equal or greater than 8,
- wherein 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-1 1-oxo-6, 1 1-dihydro-5H-benxo[b]carbazole-3-carbonitrile hydrochloride is dispersed in the matrix formed by surfactants A and B, and
- wherein the pharmaceutical composition is obtainable by:
- a) melting surfactant A,
- b) mixing melted surfactant A and liquid surfactant B, and
- c) suspending 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-1 1-oxo-6,1 1-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride in the obtained mixture.
6 more elements
Dependencies are inferred from the claim text.